Genentech’s Gazyva wins first FDA approval for primary membranous nephropathy
- Gazyva (obinutuzumab) is approved for adults with primary membranous nephropathy at risk of progression, to induce remission of proteinuria.
- In the Phase III MAJESTY study, complete remission at week 104 was 36.1% with Gazyva and 5.7% with tacrolimus.
- Overall remission at week 104 was 50% with Gazyva and 12.9% with tacrolimus.
- The European Medicines Agency is also reviewing Gazyva for primary membranous nephropathy.
FDA approval
The FDA approved Genentech’s Gazyva (obinutuzumab) for adults with primary membranous nephropathy (pMN) at risk of disease progression, to induce remission of proteinuria. It is the first FDA-approved treatment specifically for the condition.
Phase III results
Approval was based on the Phase III MAJESTY study of 142 adults randomized to Gazyva or tacrolimus. At week 104, complete remission of proteinuria was achieved by 36.1% of patients receiving Gazyva versus 5.7% receiving tacrolimus. Overall remission at week 104 was 50% versus 12.9%. No new safety signals were identified.
Condition and regulatory activity
pMN is a chronic autoimmune disease that damages the kidney’s filtering units, causing protein to leak into urine and potentially leading to irreversible kidney damage and kidney failure. Gazyva is also approved for idiopathic nephrotic syndrome and lupus nephritis. The European Medicines Agency is reviewing data on Gazyva for pMN.
Source: Genentech